Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in patients with dual diagnosis of migraine and medication overuse headache. EudraCT Number 2021-003049-40. Role: Local PI. Sponsor institution: H. Lundbeck A/S.
CandMig 3 Study - Candesartan for migraine prevention: A multicentre, binational, triple blind, placebo controlled, parallel group study of two doses of candesartan (8 and 16 mg). EudraCT Number 2019-003386-18. Role: Local PI. Sponsor institution: St. Olav’s Hospital, Trondheim.
MiBlock Study - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatmentrefractory chronic migraine: A randomized, placebo-controlled, triple-blind (blinded statistician), multicentre, parallel group proof-of-concept, phase 3 study. EudraCT Number 2018-004053-24. Role: Sub-PI. Sponsor institution: St. Olav’s Hospital and NTNU, Trondheim.
AIM Study - Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes: A double blind, randomised, placebo controlled, multicentre trial Role: Sub-PI. Sponsor institution: OUH.
Argren MB, Engstrand H, Husøy AK, Zwart JA, Winsvold BS(2024) The PopHEAD study: a population-based, cross-sectional study on headache burden in Norway: methods and validation of questionnaire-based diagnoses J Headache Pain, 25(1), 201 DOI 10.1186/s10194-024-01901-4, PubMed 39567888
Engstrand H, Revdal E, Argren MB, Hagen K, Zwart JA, Brodtkorb E, Winsvold BS(2024) Relationship between migraine and epilepsy in a large population-based cohort: The HUNT Study Eur J Neurol, 31(12), e16496 DOI 10.1111/ene.16496, PubMed 39331386
Hagen K, Winsvold BS, Bjørk MH, Tronvik E, Mathiesen LB, Ofte HK, Lundqvist C, Sønnervik J, Bäcklund N(2024) Room for improvement in the follow-up for unilateral headache with autonomic symptoms Tidsskr Nor Laegeforen, 144(7) DOI 10.4045/tidsskr.24.0184, PubMed 38832616